Molecular Formula | C18H20ClN3O |
Molar Mass | 329.82 |
Melting Point | 178.5-179.5°C |
Boling Point | 553.1°C at 760 mmHg |
Flash Point | 288.3°C |
Solubility | H2O: >5mg/mL |
Vapor Presure | 1.47E-12mmHg at 25°C |
Appearance | solid |
Color | white |
pKa | 7.4(at 25℃) |
Storage Condition | Inert atmosphere,Store in freezer, under -20°C |
Use | For the treatment of Vomit caused by chemotherapy, radiotherapy and surgery |
In vivo study | Ondansetron reduced withdrawal symptoms such as increased defecation, jumping and wet dog-like shaking intensity, increased their pain threshold for reduced withdrawal, but did not change in the production of urination, rectal temperature or salivation. Ondansetron and granisetron significantly enhanced glass bead gastric emptying and increased cisplatin-induced slowing of gastric emptying in rats. Ondansetron exhibited a biphasic dose-response curve with antidepressant-like effects at 0.1 mg/kg in forced swimming and tail suspension tests in mice. Ondansetron pretreatment enhanced the antidepressant effects of fluoxetine and venlafaxine, but did not affect the effects of desipramine or 8-hydroxy-2-(di-n-propylamino) tetralin. Ondansetron(10 mg/kg) reversed hyperactivity in the open field and reduced the proportional term and time to open arms in the elevated plus maze. Ondansetron(0.01 mg/kg instead of 0.1 mg/kg), a selective and potent 5HT3 receptor antagonist, was shown to be effective in blocking the interruption of LI induced by ampetamine. Ondansetron was able to attenuate the increased dopamine activity, resulting in a pharmacological similarity to ampetamine, without affecting the baseline dopamine activity. Ondansetron contributes to the performance of adult and elderly animals and inhibits the impairment of scopolamin, electrosions or ibotenic acid-induced adaptation. Ondansetron and arecoline antagonize the damage induced by scopolamin. |
Risk Codes | R25 - Toxic if swallowed R36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S37/39 - Wear suitable gloves and eye/face protection S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
UN IDs | UN 2811 6.1/PG 3 |
WGK Germany | 3 |
RTECS | FE6375500 |
HS Code | 29339900 |
Hazard Class | 6.1(a) |
Packing Group | II |
biological activity | Ondansetron HCl (GR 38032F) is a serotonin 5-HT3 receptor antagonist. |
target | TargetValue 5-HT3 |
Target | Value | in vivo studies | Ondansetron reduce withdrawal symptoms, such as increased defecation, jumping and wet dog-like jitter, and increase their pain threshold for reducing withdrawal, but there is no change in urination, anal temperature or salivation. Ondansetron and granisetron significantly enhanced gastric emptying of glass beads and slowed down cisplatin induced by gastric emptying rats. In forced swimming and tail suspension tests in mice, Ondansetron showed a biphasic dose-response curve with antidepressant-like effects at 0.1 mg/kg. Ondansetron pretreatment enhanced the antidepressant effects of fluoxetine and venlafaxine, but did not affect the effects of desipramine or 8-hydroxy-2-(di-n-propylamino) tetralin. Ondansetron(10 mg/kg) reversed ADHD in the open field and reduced the time to open arms in the proportional term and the elevated cross maze. Ondansetron(0.01 mg/kg instead of 0.1 mg/kg), a selective and effective 5HT3 receptor antagonist, was proved to be effective in blocking the interruption of amphetamine-induced LI. Ondansetron can reduce the activity of increasing dopamine, producing pharmacology similar to amphetamine without affecting baseline dopamine activity. Ondansetron contributes to the performance of adult and old animals and inhibits scopolamine, electrolesions or ibotenic acid-induced impairment of adaptation. Ondansetron and arecoline antagonize scopolamine-induced damage. |